title: Letter by Giral et al regarding article, "lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER trial (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin)".
authors.affiliation: Institut E3M, Pole Coeur et Métabolisme, Groupe Hospitalier Pitié Salpétrière, AP/HP, Paris FranceInstitute for Cardiovascular, Metabolic, and Nutritional Diseases and UMRS 1166, National Institute for Health and Medical Research (INSERM) and Pierre et Marie Curie University, Paris, France.
authors.forename: Philippe
authors.initials: P
authors.lastname: Giral
authors.affiliation: Institute for Cardiovascular, Metabolic and Nutritional Diseases, National Institute for Health and Medical Research (INSERM) and Pierre et Marie Curie University, Paris, France.
authors.forename: Dominique
authors.initials: D
authors.lastname: Simon
authors.affiliation: Institute for Cardiovascular, Metabolic, and Nutritional Diseases and UMRS 1166, National Institute for Health and Medical Research (INSERM) and Pierre et Marie Curie University, Paris, France.
authors.forename: M John
authors.initials: MJ
authors.lastname: Chapman
mesh_terms: D002318:Cardiovascular Diseases; D005260:Female; D005464:Fluorobenzenes / Q000008:administration & dosage*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage*; D017270:Lipoprotein(a) / Q000097:blood*; D008297:Male; D011743:Pyrimidines / Q000008:administration & dosage*; D013449:Sulfonamides / Q000008:administration & dosage*
chemical_list: D005464:Fluorobenzenes; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D017270:Lipoprotein(a); D011743:Pyrimidines; D013449:Sulfonamides